ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage specialty biopharmaceutical company focused on developing therapeutics for patients with rare kidney diseases and inflammasome-mediated inflammatory disorders. The company entered public markets through a SPAC business combination completed in 2022 and has since traded on Nasdaq under the ticker ZVSA. Its November 2023 Form 8-K filing reflects continued SEC reporting obligations as a post-merger public entity operating in the biotechnology and specialty pharma sector. ZyVersa's pipeline centers on renal and inflammatory disease pathways, placing it within a closely watched subset of SPAC-backed biotech issuers. For complete deal history, sponsor details, and post-merger data on ZVSA and thousands of other SPAC transactions, sign up for full access at SpacDesk.